Clinical trials
catalyst calendar across sponsors →Studies where MAIA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC) · FINRA short interest 6.8 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLCRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: 6-Thio-2'-Deoxyguanosine, Cemiplimab | Carcinoma, Non-Small-Cell Lung | 227 | 2027-09-30 | in 407 d | 2026-05-13 |
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Vinorelbine, Gemcitabine alone | Carcinoma, Non-Small -Cell Lung | 300 | 2027-07-31 | in 346 d | 2026-01-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19